The Dow Jones Industrial Average (^DJI) was up 230.81 (+0.47%) points today, Friday, February 20th, 2026, closing at a record 49,625.97. Similarly, Dow Futures (YM=F) climbed 221.00 (+0.45%) to 49,679.00. The primary narrative driving the market was a favorable economic data release regarding cooling inflation, which bolstered investor confidence in a potential Federal Reserve pivot. This shift in sentiment favored high-growth technology and e-commerce stocks, which led the broader index higher despite loca ...

A month has gone by since the last earnings report for Johnson & Johnson (JNJ) . Shares have added about 13% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Johnson & Johnson before we dive into how investors and analysts ...

The biotech space this week witnessed significant key milestones, including FDA approvals, NDA path-setting meetings, rejections, licensing agreements, and oncology drug acquisitions. The clinical trial arena achieved positive results in therapeutic areas such as idiopathic nephrotic syndrome, age-related macular degeneration, ulcerative colitis, plaque psoriasis, obesity, autoimmune and inflammatory diseases.Let us unpack the key developments and milestones of this week. FDA Approvals & Rejections NRx Pha ...

Johnson & Johnson is preparing a potential sale of its orthopedics unit, in a deal that could top $20 billion, with the company eyeing private equity firms as the most likely buyers, a source familiar with the matter has told Reuters.The company did not immediately respond to a Reuters request for comment.J&J last year said it had planned to separate its orthopedics unit, known as DePuy Synthes, into a standalone company within the next 18 to 24 months, marking its second major spinoff in two years as it sh ...

Core Viewpoint - The company emphasizes providing actionable and clear investment ideas through independent research, aiming to help members outperform the S&P 500 and mitigate significant losses during market volatility [1] Group 1 - The service offers at least one in-depth article per week focused on investment ideas [1] - Members have reportedly achieved better performance than the S&P 500 while avoiding substantial drawdowns in both equity and bond markets [1]

The Dow Jones Industrial Average (^DJI) was down 267.50 (-0.5386%) points today, closing at 49,395.16. Market sentiment turned cautious as Dow Futures (YM=F) also dropped 300.00 (-0.6034%) to 49,422.00. The primary narrative was a hawkish shift in monetary policy expectations following a higher-than-expected Producer Price Index (PPI) report. This economic data fueled concerns that the Federal Reserve may delay anticipated interest rate cuts, triggering a broad sell-off in rate-sensitive sectors as investor ...

 LAZCLUZE®In MARIPOSA (n=421), the most common adverse reactions (ARs) (20%) were rash (86%), nail toxicity (71%), infusion-related reactions (IRRs) (RYBREVANT®) (63%), musculoskeletal pain (47%), stomatitis (43%), edema (43%), VTE (36%), paresthesia (35%), fatigue (32%), diarrhea (31%), constipation (29%), COVID-19 (26%), hemorrhage (25%), dry skin (25%), decreased appetite (24%), pruritus (24%), and nausea (21%). The most common Grade 3 or 4 laboratory abnormalities (2%) were decreased albumin (8%), decr ...

来源：滚动播报 据知情人士透露，强生酝酿出售其计划分拆的骨科业务部门，大型私募股权机构已开始关注潜在交易。 因讨论未公开消息而要求匿名的知情人士表示，名为DePuy Synthes的业务在出售时的估值可能超过200 亿美元。这些知情人士表示，强生在整理DePuy Synthes的相关文件和财务资料，以便在未来几周与潜 在买家会面。他们还称，多家大型私募股权公司正考虑联合收购该业务。 ...

Johnson & Johnson is preparing a potential sale of the orthopedics unit that it has been planning to separate, with big buyout firms already circling, Bloomberg News reported on Thursday, citing peopl... ...

Johnson & Johnson on Wednesday announced plans to invest more than $1 billion in a next-generation manufacturing facility that will produce advanced cell therapy technologies. The facility will be located in Montgomery County, Pennsylvania, and Johnson & Johnson said the move will expand its U.S. manufacturing capacity along with its pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.Johnson & Johnson added that the facility will have cutting-edge manufacturing proc ...